ArticleInternational journal of clinical and experimental pathology2018
MiR-223 inhibits the proliferation, invasion and EMT of nasopharyngeal carcinoma cells by targeting SSRP1.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Insights into FACT in Cancers with Targeted Therapeutic Implications.Molecular and cellular biology · 2026Review
- SFPQ promotes the proliferation, migration and invasion of hepatocellular carcinoma cells and is associated with poor prognosis.American journal of cancer research · 2023Article
- Article
- SSRP1 affects the growth and apoptosis of gastric cancer cells through AKT pathway.Journal of medical biochemistry · 2022Article
- miRNA-223 expression in patient-derived eutopic and ectopic endometrial stromal cells and its effect on epithelial-to-mesenchymal transition in endometriosis.Clinics (Sao Paulo, Brazil) · 2022Article
- miR-26a-5p suppresses nasopharyngeal carcinoma progression by inhibiting PTGS2 expression.Cell cycle (Georgetown, Tex.)Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aberrant expression of microRNAs (miRNAs) has been found in various types of cancer and is associated with tumorigenesis and metastasis. However, the expression and function of miR-223 in nasopharyngeal carcinoma (NPC) remain unclear. The present study demonstrated that miR-223 was downregulated in NPC cell lines. The ectopic expression of miR-223 dramatically suppressed cell proliferation, invasion and epithelial-mesenchymal transition (EMT). Moreover, a luciferase reporter assay identified the structure-specific recognition protein (SSRP1) as a novel direct target of miR-223. SSRP1 expression was upregulated in NPC cell lines and the overexpression of miR-233 markedly reduced the expression of SSRP1. Furthermore, SSRP1 was involved in miR-223-regulated NPC cell proliferation, invasion, and EMT. Taken together, these results indicate that miR-223 functions as a tumor suppressor miRNA in NPC and that its suppressive effects are primarily mediated by repressing SSRP1 expression and inhibiting EMT.
Indexed as
Identifiers
31949834PMC6962943W3012989828What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.